Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC GENE THERAPY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER FIVE ANALYSIS
5 UPDATE ON GERMLINE GENE THERAPY
5.1 GERMLINE GENE THERAPY
6 ASIA PACIFIC GENE THERAPY MARKET, MO
6.1 DRIVERS
6.1.1 NOVEL APPROACHES TO GENE THERAPY
6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS
6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE
6.2 RESTRAINTS
6.2.1 HIGH COST OF GENE THERAPY
6.2.2 ETHICAL AND SAFETY CONCERNS
6.2.3 COMPLEXITY OF GENE THERAPY
6.3 OPPORTUNITIES
6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS
6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS
6.4 CHALLENGES
6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS
6.4.2 LONG-TERM SAFETY AND EFFICACY
7 ASIA PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE
7.1 OVERVIEW
7.2 VIRAL VECTOR
7.2.1 ADENOVIRUS
7.2.2 RETROVIRUS
7.2.3 LENTIVIRUS
7.2.4 ADENO-ASSOCIATED VIRUS
7.2.5 VACCINIA VIRUS
7.2.6 HERPES SIMPLEX VIRUS
7.2.7 OTHERS
7.3 NON-VIRAL VECTOR
7.3.1 LIPOFECTION
7.3.2 INJECTION OF NAKED DNA
8 ASIA PACIFIC GENE THERAPY MARKET, BY METHOD
8.1 OVERVIEW
8.2 EX-VIVO
8.3 IN-VIVO
9 ASIA PACIFIC GENE THERAPY MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 ONCOLOGICAL DISORDERS
9.3 CARDIOVASCULAR DISEASES
9.4 INFECTIOUS DISEASES
9.5 RARE DISEASES
9.6 NUEROLOGICAL DISORDERS
9.7 OTHER DISEASES
10 ASIA PACIFIC GENE THERAPY MARKET, BY END USER
10.1 OVERVIEW
10.2 CANCER INSTITUTES
10.3 HOSPITALS
10.4 RESEARCH INSTITUTES
10.5 OTHERS
11 ASIA PACIFIC GENE THERAPY MARKET, BY REGION
11.1 ASIA-PACIFIC
11.1.1 CHINA
11.1.2 JAPAN
11.1.3 SOUTH KOREA
11.1.4 INDIA
11.1.5 AUSTRALIA
11.1.6 SINGAPORE
11.1.7 THAILAND
11.1.8 MALAYSIA
11.1.9 INDONESIA
11.1.10 PHILIPPINES
11.1.11 REST OF ASIA-PACIFIC
12 ASIA PACIFIC GENE THERAPY MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
13 COMPANY PROFILES
13.1 BIOGEN
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 SWOT ANALYSIS
13.1.5 PRODUCT PORTFOLIO
13.1.6 RECENT DEVELOPMENT
13.2 KITE PHARMA
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 COMPANY SHARE ANALYSIS
13.2.4 SWOT ANALYSIS
13.2.5 PRODUCT PORTFOLIO
13.2.6 RECENT DEVELOPMENT
13.3 NOVARTIS AG
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 SWOT ANALYSIS
13.3.5 PRODUCT PORTFOLIO
13.3.6 RECENT DEVELOPMENTS
13.4 BRISTOL-MYERS SQUIBB COMPANY.
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 SWOT ANALYSIS
13.4.5 PRODUCT PORTFOLIO
13.4.6 RECENT DEVELOPMENT
13.5 OXFORD BIOMEDICA
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 COMPANY SHARE ANALYSIS
13.5.4 SWOT ANALYSIS
13.5.5 PRODUCT PORTFOLIO
13.5.6 RECENT DEVELOPMENTS
13.6 AGC BIOLOGICS
13.6.1 COMPANY SNAPSHOT
13.6.2 PRODUCT PORTFOLIO
13.6.3 RECENT DEVELOPMENT
13.7 ANGES, INC
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENT
13.8 AMGEN INC.
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENT
13.9 BLUEBIRD BIO, INC.
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENT
13.1 CHIESI FARMACEUTICI S.P.A
13.10.1 COMPANY SNAPSHOT
13.10.2 REVENUE ANALYSIS
13.10.3 PRODUCT PORTFOLIO
13.10.4 RECENT DEVELOPMENT
13.11 DENDREON PHARMACEUTICALS LLC
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
13.12 ENZYVANT THERAPEUTICS GMBH
13.12.1 COMPANY SNAPSHOT
13.12.2 RODUCT PORTFOLIO
13.12.3 RECENT DEVELOPMENT
13.13 FERRING B.V.
13.13.1 COMPANY SNAPSHOT
13.13.2 PRODUCT PORTFOLIO
13.13.3 RECENT DEVELOPMENT
13.14 JANSSEN PHARMACEUTICALS, INC.
13.14.1 COMPANY SNAPSHOT
13.14.2 PRODUCT PORTFOLIO
13.14.3 RECENT DEVELOPMENT
13.15 MALLINCKRODT.
13.15.1 COMPANY SNAPSHOT
13.15.2 REVENUE ANALYSIS
13.15.3 PRODUCT PORTFOLIO
13.15.4 RECENT DEVELOPMENT
13.16 ORCHARD THERAPEUTICS PLC.
13.16.1 COMPANY SNAPSHOT
13.16.2 REVENUE ANALYSIS
13.16.3 PRODUCT PORTFOLIO
13.16.4 RECENT DEVELOPMENT
13.17 SHANGHAI SUNWAY BIOTECH CO., LTD.
13.17.1 COMPANY SNAPSHOT
13.17.2 PRODUCT PORTFOLIO
13.17.3 RECENT DEVELOPMENT
13.18 SIBONO
13.18.1 COMPANY SNAPSHOT
13.18.2 PRODUCT PORTFOLIO
13.18.3 RECENT DEVELOPMENT
13.19 SPARK THERAPEUTICS, INC.
13.19.1 COMPANY SNAPSHOT
13.19.2 PRODUCT PORTFOLIO
13.19.3 RECENT DEVELOPMENT
13.2 UNIQURE NV.
13.20.1 COMPANY SNAPSHOT
13.20.2 REVENUE ANALYSIS
13.20.3 PRODUCT PORTFOLIO
13.20.4 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
List of Table
TABLE 1 ASIA PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 2 ASIA PACIFIC VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 ASIA PACIFIC VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 4 ASIA PACIFIC NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 ASIA PACIFIC NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 6 ASIA PACIFIC GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 7 ASIA PACIFIC EX-VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 ASIA PACIFIC IN –VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 ASIA PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 10 ASIA PACIFIC ONCOLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 ASIA PACIFIC CARDIOVASCULAR DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 ASIA PACIFIC INFECTIOUS DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 ASIA PACIFIC RARE DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 ASIA PACIFIC NEUROLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 ASIA PACIFIC OTHER DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 ASIA PACIFIC GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 17 ASIA PACIFIC CANCER INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 ASIA PACIFIC HOSPITALS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 ASIA PACIFIC RESEARCH INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 ASIA PACIFIC OTHERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 ASIA-PACIFIC GENE THERAPY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 22 ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 23 ASIA-PACIFIC VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 24 ASIA-PACIFIC NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 25 ASIA-PACIFIC GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 26 ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 27 ASIA-PACIFIC GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 28 CHINA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 29 CHINA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 30 CHINA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 31 CHINA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 32 CHINA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 33 CHINA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 34 JAPAN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 35 JAPAN VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 36 JAPAN NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 37 JAPAN GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 38 JAPAN GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 39 JAPAN GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 40 SOUTH KOREA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 41 SOUTH KOREA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 42 SOUTH KOREA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 43 SOUTH KOREA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 44 SOUTH KOREA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 45 SOUTH KOREA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 46 INDIA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 47 INDIA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 48 INDIA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 49 INDIA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 50 INDIA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 51 INDIA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 52 AUSTRALIA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 53 AUSTRALIA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 54 AUSTRALIA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 55 AUSTRALIA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 56 AUSTRALIA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 57 AUSTRALIA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 58 SINGAPORE GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 59 SINGAPORE VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 60 SINGAPORE NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 61 SINGAPORE GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 62 SINGAPORE GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 63 SINGAPORE GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 64 THAILAND GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 65 THAILAND VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 66 THAILAND NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 67 THAILAND GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 68 THAILAND GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 69 THAILAND GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 70 MALAYSIA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 71 MALAYSIA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 72 MALAYSIA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 73 MALAYSIA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 74 MALAYSIA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 75 MALAYSIA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 76 INDONESIA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 77 INDONESIA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 78 INDONESIA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 79 INDONESIA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 80 INDONESIA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 81 INDONESIA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 82 PHILIPPINES GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 83 PHILIPPINES VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 84 PHILIPPINES NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 85 PHILIPPINES GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 86 PHILIPPINES GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 87 PHILIPPINES GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 88 REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 ASIA PACIFIC GENE THERAPY MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC GENE THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC GENE THERAPY MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC GENE THERAPY MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC GENE THERAPY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC GENE THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC GENE THERAPY MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 ASIA PACIFIC GENE THERAPY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC GENE THERAPY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC GENE THERAPY MARKET: SEGMENTATION
FIGURE 11 THE INCREASING PREVALENCE OF GENETIC DISORDERS AND GROWING DEMAND FOR PERSONALIZED MEDICINE ARE EXPECTED TO DRIVE THE GROWTH OF THE ASIA PACIFIC GENE THERAPY MARKET FROM 2023 TO 2030
FIGURE 12 THE VIRAL VECTOR SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC GENE THERAPY MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC GENE THERAPY MARKET
FIGURE 14 ASIA PACIFIC GENE THERAPY MARKET: BY VECTOR TYPE, 2022
FIGURE 15 ASIA PACIFIC GENE THERAPY MARKET: BY VECTOR TYPE, 2023-2030 (USD MILLION)
FIGURE 16 ASIA PACIFIC GENE THERAPY MARKET: BY VECTOR TYPE, CAGR (2023-2030)
FIGURE 17 ASIA PACIFIC GENE THERAPY MARKET: BY VECTOR TYPE, LIFELINE CURVE
FIGURE 18 ASIA PACIFIC GENE THERAPY MARKET: BY METHOD, 2022
FIGURE 19 ASIA PACIFIC GENE THERAPY MARKET: BY METHOD, 2023-2030 (USD MILLION)
FIGURE 20 ASIA PACIFIC GENE THERAPY MARKET: BY METHOD, CAGR (2023-2030)
FIGURE 21 ASIA PACIFIC GENE THERAPY MARKET: BY METHOD, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC GENE THERAPY MARKET: BY APPLICATION, 2022
FIGURE 23 ASIA PACIFIC GENE THERAPY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 24 ASIA PACIFIC GENE THERAPY MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 ASIA PACIFIC GENE THERAPY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC GENE THERAPY MARKET: BY END USER, 2022
FIGURE 27 ASIA PACIFIC GENE THERAPY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 ASIA PACIFIC GENE THERAPY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 ASIA PACIFIC GENE THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC GENE THERAPY MARKET: SNAPSHOT (2022)
FIGURE 31 ASIA-PACIFIC GENE THERAPY MARKET: BY COUNTRY (2022)
FIGURE 32 ASIA-PACIFIC GENE THERAPY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 ASIA-PACIFIC GENE THERAPY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 ASIA-PACIFIC GENE THERAPY MARKET: VECTOR TYPE (2023-2030)
FIGURE 35 ASIA PACIFIC GENE THERAPY MARKET: COMPANY SHARE 2022 (%)
